

**For Immediate Release: Friday, 4 October 2019**

**MEDIA RELEASE  
ASX: GLH**

### **Partially Underwritten Non-Renounceable Pro Rata Entitlement Offer**

- 1 for 4 non-renounceable pro rata entitlement offer of up to 8,419,648 shares and 4,209,824 free attaching unlisted options to raise up to \$1,010,358
- The Company's Directors have each committed to take up their full entitlements under the Offer
- Entities associated with the Directors have committed to underwrite up to \$225,400 of the shortfall
- Proceeds from the Offer will be used to fund development of the Company's Software as a Service platforms and support the development of export markets as well as providing the Company with additional working capital

Global Health Limited (ASX: GLH) (the **Company**) is pleased to announce that it is undertaking a partially underwritten non-renounceable pro rata entitlement offer to eligible shareholders of approximately 8,419,648 new fully paid ordinary shares (**New Shares**) to raise up to up to \$1,010,358 (**Offer**).

#### **About the Offer**

Under the Offer, Eligible Shareholders have the opportunity to subscribe for one New Share for every four fully paid ordinary shares (**Shares**) they hold at 7:00pm (Melbourne time) on Wednesday, 9 October 2019 (**Record Date**), at the price of \$0.12 per New Share (**Offer Price**). The Company will apply for quotation of the New Shares on ASX.

The Offer Price of \$0.12 per New Share represents a discount of 25% to the last closing price of Shares on ASX on Thursday, 3 October 2019 of \$0.16 (16 cents).

Pursuant to the Offer, each Eligible Shareholder who subscribes for New Shares will receive one free attaching option (**New Option**) for every two New Shares they are issued pursuant to the Offer. Each New Option will entitle the holder to one New Share on exercise, will have an exercise price of \$0.25 (25 cents) and will expire three years after its date of issue. The Company will not be applying for quotation of the New Options.

There is no minimum subscription under the Offer.

The Offer is non-renounceable which means that the entitlements to participate in the Offer are not transferable and cannot be traded on the ASX (or any other exchange), or transferred privately.

The Company's Directors have separately committed to not only take up their full entitlement under the Offer, representing approximately 57% of New Shares available under the Offer, but to also partially underwrite any shortfall.

The proceeds of the Offer will be used to fund development of the Company's Software as a Service platforms and support the development of export markets as well as providing the Company with additional working capital.

### **Shortfall Facility**

The Offer will include a shortfall facility, under which Eligible Shareholders who have taken up their full entitlement under the Offer can apply to take up additional New Shares in excess of their pro rata entitlement, that have not been taken up by other Shareholders (**Shortfall Facility**). There will be no maximum allocation under the Shortfall Facility, however, any such applications will be assessed by the Board on a case by case basis, and any allocation will be at the Board's discretion and may be subject to scale back.

### **Underwriting arrangements**

The Offer will be partially underwritten to an aggregate value of \$225,400 by the Directors of the Company or entities associated with the Directors (**Underwriters**).

Each of the Underwriters has separately entered into an Underwriting Agreement with the Company pursuant to which, it has agreed to underwrite the Offer to a specified dollar value (**Underwriting Commitment**), as follows:

- Micron Holdings Pty Ltd ACN 009 154 410, an entity associated with Mathew Cherian, has agreed to subscribe for up to \$150,000 of any shortfall;
- Beachtown Holdings Pty Ltd ACN 073 834 983, an entity associated with Steven Pynt, has agreed to subscribe for up to \$20,400 of any shortfall;
- Roxanne Investments Pty Ltd ACN 069 358 747, an entity associated with Grant Smith, has agreed to subscribe for up to \$30,000 of any shortfall; and
- Robert Knowles has agreed to subscribe for up to \$25,000 of any shortfall in his personal capacity.

In consideration for their respective Underwriting Commitments, each Underwriter will receive a fee equal to 5% (inclusive of any applicable GST) of the dollar amount of their Underwriting Commitment.

No Underwriter will be permitted to participate in the Shortfall Facility and New Shares will be allocated in priority to the applicants under the Shortfall Facility before any New Shares are allocated to any Underwriter.

Further details about the Underwriters and the terms of the underwriting arrangements provided in the Prospectus which is available on ASX's website.

## Shortfall Placement

If there are additional New Shares remaining after completion of the Offer, the Directors reserve the right to place the balance of the New Shares at their discretion within 3 months of the Offer closing, in accordance with Exception 3 of ASX Listing Rule 7.2.

## Prospectus

The Offer is being carried out pursuant to a transaction-specific prospectus issued under section 713 of the Corporations Act 2001 (Cth) lodged with the Australian Securities and Investments Commission and ASX today, Friday, 4 October 2019 (**Prospectus**). The Prospectus is available from ASX's website ([www.asx.com.au](http://www.asx.com.au)) and the Company's website ([www.global-health.com](http://www.global-health.com)).

Shareholders may view all of the Company's ASX releases relating to the Offer on the ASX website (company announcements section, ASX code: GLH) at [www.asx.com.au](http://www.asx.com.au).

## Eligible Shareholders

The Company is making the Offer available to Eligible Shareholders only. Eligible Shareholders are persons who are registered as shareholders of the Company on the Record Date and have a registered address in Australia or New Zealand.

Eligible Shareholders should read the Prospectus carefully and in its entirety before deciding whether to participate in the Offer. Eligible Shareholders who wish to participate should follow the instructions on your personalised Entitlement and Acceptance Form accompanying the Prospectus. If you choose to do nothing in respect of your entitlement, your entitlement will lapse, you will not receive any New Shares and your interest in the Company will be diluted.

## Ineligible Shareholders

The Company has determined that it is unreasonable to make the Offer generally available to shareholders with registered addresses outside of Australia and New Zealand (**Ineligible Shareholders**) due to:

1. the small number of shareholders with registered addresses outside of these countries; and
2. the cost of complying with the legal and other regulatory requirements in each of the countries concerned.

The Offer will not be extended to Ineligible Shareholders and they will not receive a copy of the Prospectus or an Entitlement and Acceptance Form. Ineligible Shareholders are not required to take any action in relation to the Offer, but there may be financial implications for you as a result of the Offer that you should be aware of.

## Indicative Timetable

The Offer will be conducted according to the following indicative timetable:

Activity	Date
<b>Announcement of the Offer</b>	Friday, 4 October 2019
<b>Release of the Prospectus and Appendix 3B with ASX</b>	Friday, 4 October 2019
<b>Ex Date</b> The date from which Shares commence trading without the entitlement to participate in the Offer	Tuesday, 8 October 2019
<b>Record Date</b> The date for determining Entitlements of Eligible Shareholders to participate in the Offer	7:00PM (Melbourne time) on Wednesday, 9 October 2019
<b>Prospectus and Entitlement and Acceptance Form dispatched</b>	Monday, 14 October 2019
<b>Offer Opening Date</b> The first day for Applications under the Offer	Monday, 14 October 2019
<b>Offer Closing Date</b> The final day for Applications under the Offer	5:00pm (Melbourne time) on Monday, 4 November 2019
<b>Deferred settlement trading</b> New Shares issued quoted on a deferred settlement basis	Tuesday, 5 November 2019
<b>Allotment of New Shares and Options issued under the Offer</b>	Monday, 11 November 2019
<b>Holding statements for New Shares and Options issued under the Offer dispatched</b>	Monday, 11 November 2019
<b>Normal Trading</b> Normal trading of New Shares on ASX expected to commence	Tuesday, 12 November 2019

*This Timetable is indicative only and subject to change without notice. The Directors may vary any or all of the dates of the Offer, including the Closing Date, subject to the Listing Rules and the Corporations Act 2001 (Cth). An extension of the Closing Date will delay the anticipated date for issue of the New Shares.*

*The Directors also reserve the right not to proceed with the whole or part of the Offer any time prior to allotment and issue of the New Shares. In that event, the relevant Application Monies (without interest) will be returned in full to Applicants.*

Full details of the Offer will be contained in the Prospectus that will be mailed to all Eligible Shareholders who are registered on the Record Date. Eligible Shareholders should read the Prospectus carefully.

## Current Optionholders

Existing optionholders may participate in the Offer upon exercise of their vested options. The Company will send a letter to its optionholders to notify them of their right to participate in the Offer upon exercise of their vested options.

## Further Information

For further information on the Offer, you can contact the Company's Share Registry, Link Market Services, on +61 1300 650 320 between 8:30am to 5:30pm (Melbourne time) Monday to Friday. If you have any further questions, you should contact your stockbroker, solicitor, accountant or other professional advisor.

Copies of the Prospectus, together with a personalised Entitlement and Acceptance Form, will be mailed to all Eligible Shareholders in accordance with the timetable set out above.

Yours faithfully



Steven Pynt  
**Chairman**  
**Global Health Limited**

### Summary Information

The following disclaimer applies to this announcement and any information contained in it. The information in this announcement is of general background and does not purport to be complete. It should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with ASX Limited, which are available at [www.asx.com.au](http://www.asx.com.au). You are advised to read this disclaimer carefully before reading or making any other use of this announcement or any information contained in this announcement. In accepting this announcement, you agree to be bound by the following terms and conditions including any modifications to them.

For further information about this announcement, please email: [investor.relations@global-health.com](mailto:investor.relations@global-health.com)

### About Global Health Limited

Global Health (ASX:GLH) is a leading provider of Digital Health solutions to the Australasian Healthcare Industry. Innovation, consumer-centricity and connectivity are the foundations of the Company's vision of 'Connecting Clinicians and Consumers.'

Global Health helps streamline the delivery of healthcare and provide better health outcomes across various health sectors, including acute and community settings.

Global Health offers a range of solutions to help health businesses be more efficient and deliver excellent patient care. These include: electronic medical records, patient administration systems, practice management systems, clinical records, secure message exchange, patient engagement platforms and consumer health records.

Find out more about Global Health Solution's at [www.global-health.com](http://www.global-health.com) or visit any of the product websites.

